5 Things to Know About Radioligand Therapy <p>Radioligand therapy is an innovative medicine that specifically targets cancer cells. Instead of using chemicals to kill the cancer, it uses radioactivity, a sub-atomic physical phenomenon that can damage cells. Several radioligand therapies, which also may be called radiopharmaceutical therapy or theranostics, are approved for the treatment of a range of cancers, including prostate cancer ... <a class="read-more" href="https://blog.dana-farber.org/insight/2025/09/5-things-to-know-about-radioligand-therapy/" title="5… Dana-Farber Cancer Institute September 8, 2025 Original source
Published Population Pharmacokinetic Models of Imatinib Perform Poorly on TDM Data from Pediatric Patients Background <p>Population pharmacokinetic models can potentially provide suggestions for an initial dose and the magnitude of dose adjustment during therapeutic drug monitoring procedures of imatinib. Several population pharmacokinetic models for imatinib have been developed over the last two decades. However, their predictive performance is still unknown when extrapolated to different populations, especially children.</p> Objective <p>This study aimed to evaluate the… Targeted Oncology September 8, 2025 Original source
A common supplement could reverse the hidden harm of sucralose Sucralose, the sugar substitute in many diet products, may weaken cancer immunotherapy by altering gut bacteria and reducing arginine levels needed for immune cells. But supplementation with arginine or citrulline could counteract this effect, pointing to new clinical trial possibilities. ScienceDaily Cancer September 6, 2025 Original source
Dana-Farber Treats First Patient with Approved Gene Therapy for Beta Thalassemia <p>A few years ago, Oscar Diep, a 33-year-old software engineer living in Weymouth, Mass., started needing blood transfusions more often to manage a blood disorder called beta thalassemia. He also noticed that it was becoming harder for the nurses to find a vein for his infusions.  On top of this, Diep and his then girlfriend, ... <a class="read-more" href="https://blog.dana-farber.org/insight/2025/09/dana-farber-treats-first-patient-with-approved-gene-therapy-for-beta-thalassemia/" title="Dana-Farber… Dana-Farber Cancer Institute September 5, 2025 Original source
Stem Cell Transplant Recipient Forms Powerful Bond with Doctor and Donor <p>“The world needs more Dr. Soiffers – and more Nicoles.”  Such is the wisdom of Judy Mangione, 80, who credits these two individuals for the fulfilling life she is enjoying with her husband, Bob, and their combined six children and 10 grandchildren.  Robert Soiffer, MD, treated Mangione with the January 2022 stem cell transplant that ... <a class="read-more" href="https://blog.dana-farber.org/insight/2025/09/stem-cell-transplant-patient-forms-bond-with-doctor-and-donor/" title="Stem… Dana-Farber Cancer Institute September 4, 2025 Original source
Hidden viruses in our DNA could be medicine’s next big breakthrough Scientists have decoded the 3D structure of an ancient viral protein hidden in our DNA. The HERV-K Env protein, found on cancer and autoimmune cells, has a unique shape that could unlock new diagnostics and therapies. ScienceDaily Cancer September 3, 2025 Original source
Scientists discover how to wipe out breast cancer’s hidden cells Scientists at the University of Pennsylvania have shown for the first time that it’s possible to detect dormant cancer cells in breast cancer survivors and eliminate them with repurposed drugs, potentially preventing recurrence. In a clinical trial, existing medications cleared these hidden cells in most participants, leading to survival rates above 90%. The findings open a new era of proactive… ScienceDaily Cancer September 2, 2025 Original source
How long can one RSV shot protect seniors? Study shows surprising two-year shield A single RSV vaccine dose is proving to be a powerful shield for older adults, significantly reducing hospitalizations and severe illness over two consecutive RSV seasons. While protection is strongest in the first year and declines somewhat in the second, the findings highlight both the immediate benefits and the importance of ongoing monitoring. With RSV causing tens of thousands of… ScienceDaily Cancer September 2, 2025 Original source
Real-World Outcomes of T790M Mutation Testing and Sequential Osimertinib in EGFR-Positive Advanced Non-small Cell Lung Cancer: A Revisited Strategy Background <p>Epidermal growth factor receptor (EGFR)-driven non-small cell lung cancer (eLC) is a leading cause of death. The FLAURA study showed that upfront osimertinib (U-OSI) led to better overall survival (OS) than gefitinib or erlotinib, regardless of T790M status in advanced disease. However, if sequenced optimally, sequential OSI (S-OSI) in T790M-positive patients after first- or second-generation EGFR-tyrosine kinase inhibitors (F-S-EGFR-TKI)… Targeted Oncology September 2, 2025 Original source
Lithium deficiency may be the hidden spark behind Alzheimer’s Harvard scientists have uncovered that lithium, a naturally occurring element in the brain, may be the missing piece in understanding Alzheimer’s. Their decade-long research shows that lithium depletion—caused by amyloid plaques binding to it—triggers early brain changes that lead to memory loss. By testing new lithium compounds that evade plaque capture, they reversed Alzheimer’s-like damage and restored memory in mice… ScienceDaily Cancer August 29, 2025 Original source
The hidden DNA organizer linking fertility and cancer Scientists at Kyoto University have uncovered a hidden protein complex that organizes DNA in sperm stem cells, a discovery that reveals surprising ties between fertility and cancer. When this protein, called STAG3, is missing, sperm stem cells cannot mature properly, leading to infertility in mice. Even more intriguing, the same protein is found in high levels in certain immune cells… ScienceDaily Cancer August 27, 2025 Original source
Correction: Precision Oncology in Rare Endocrine and Neuroendocrine Neoplasms: Experiences and Challenges of the CCCMunich<sup>LMU</sup> Molecular Tumor Board Targeted Oncology August 27, 2025 Original source
Tiny green tea beads trap fat and melt away pounds without side effects Researchers have created plant-based microbeads that trap fat in the gut, helping rats lose weight without side effects. Unlike current drugs, the beads are safe, tasteless, and easy to mix into everyday foods. Human trials are now underway. ScienceDaily Cancer August 24, 2025 Original source
Scientists uncover sugar pathway driving aggressive childhood cancer Scientists have uncovered a hidden weakness in one of the deadliest childhood cancers. The tumors, which spread quickly and are notoriously hard to treat, rely on a sugar-processing pathway to survive and grow. By blocking this pathway, researchers were able to slow down the cancer and make it more vulnerable to treatment. This breakthrough opens the door to new therapies… ScienceDaily Cancer August 20, 2025 Original source
A new cancer vaccine just wiped out tumors in mice A breakthrough mRNA cancer vaccine has shown the ability to supercharge the effects of immunotherapy in mice, sparking hope for a universal “off-the-shelf” treatment that could fight multiple cancers. Unlike traditional vaccines designed to target specific tumor proteins, this approach simply revs up the immune system as if it were fighting a virus. The results were dramatic—when paired with checkpoint… ScienceDaily Cancer August 19, 2025 Original source
Elranatamab Fixed Dosing: A Safe, Effective, and Convenient Dosing Approach Background <p>Bispecific T-cell engagers (TCEs) are a promising modality for cancer treatment, and evaluation of dosing strategies, including utilization of body weight–based versus fixed dosing, is essential to ensure optimal therapeutic outcomes. Elranatamab is a bispecific TCE that targets B-cell maturation antigen (BCMA) on multiple myeloma cells and CD on T cells. Elranatamab is approved for relapsed or refractory multiple… Targeted Oncology August 19, 2025 Original source
Population Exposure–Response Efficacy Analysis of Elranatamab (PF-06863135) in Patients with Multiple Myeloma Background <p>Elranatamab is a heterodimeric humanized full-length bispecific antibody composed of one B-cell maturation antigen (BCMA) binding arm and one cluster of differentiation 3 (CD3) binding arm. Results from the MagnetisMM-3 study indicated deep and durable responses in patients with relapsed or refractory multiple myeloma (RRMM).</p> Objective <p>The current analysis was conducted to characterize the relationship between free (i.e., unbound)… Targeted Oncology August 18, 2025 Original source
Trojan horse bacteria sneak cancer-killing viruses into tumors Scientists have engineered a groundbreaking cancer treatment that uses bacteria to smuggle viruses directly into tumors, bypassing the immune system and delivering a powerful one-two punch against cancer cells. The bacteria act like Trojan horses, carrying viral payloads to cancer’s core, where the virus can spread and destroy malignant cells. Built-in safety features ensure the virus can’t multiply outside the… ScienceDaily Cancer August 17, 2025 Original source
MYC as a Target for Cancer Treatment: from Undruggable to Druggable? <p>MYC is one of the most frequently altered genes in cancer with an estimated 70% prevalence of deregulation. Deregulated MYC is believed to promote cancer formation/progression via multiple mechanisms including tumour cell intrinsic mechanisms, altering the tumour microenvironment and promoting host immune suppression. Owing to the high prevalence of alterations and its causative role in tumorigenesis, MYC is a highly… Targeted Oncology August 15, 2025 Original source
The 30-minute workout that could slash cancer cell growth by 30% A vigorous workout can spark anti-cancer proteins, cut cancer cell growth, and help survivors fight recurrence by reducing inflammation and improving body composition. ScienceDaily Cancer August 13, 2025 Original source